Response to: 'Correspondence on 'Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial'' by Zhao and Huang.

Wei, James Cheng-Chung; Kim, Tae-Hwan; Kishimoto, Mitsumasa; Ogusu, Naoki; Jeong, Haeyoun; Kobayashi, Shigeto

Wei, James Cheng-Chung; Kim, Tae-Hwan; Kishimoto, Mitsumasa; Ogusu, Naoki; Jeong, Haeyoun; Kobayashi, Shigeto.

Afiliação

Wei JC; Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
Kim TH; Institute of Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Kishimoto M; Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.
Ogusu N; Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.
Jeong H; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, The Republic of Korea.
Kobayashi S; Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan.

Ann Rheum Dis ; 82(7): e169, 2023 07.

Article em En | MEDLINE | ID: mdl-34172504

Assuntos

Espondiloartrite Axial; Espondilite Anquilosante; Humanos; Anticorpos Monoclonais Humanizados; Método Duplo-Cego; Resultado do Tratamento

Palavras-chave

ankylosing; biological therapy; inflammation; spondylitis; therapeutics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Espondilite Anquilosante / Espondiloartrite Axial Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google